{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:18Z","timestamp":1789398258917,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100415","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T19:38:37Z","timestamp":1646249917000},"page":"100415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study"],"prefix":"10.1016","volume":"7","author":[{"given":"N.","family":"Izawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shiokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Onuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hamaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kasugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100415_bib1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100415_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti\u2013PD-1 therapy for advanced non\u2013small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100415_bib3","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2022.100415_bib4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00262-018-2203-3","article-title":"Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC","volume":"67","author":"Matsuura","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmoop.2022.100415_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cyto.b.20067","article-title":"Detection of various platelet-associated immunoglobulins by flow cytometry in idiopathic thrombocytopenic purpura","volume":"68","author":"Nishioka","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.esmoop.2022.100415_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.esmoop.2022.100415_bib7","first-page":"150239","article-title":"High prevalence of antinuclear antibodies in children with thyroid autoimmunity","volume":"2014","author":"Segni","year":"2014","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.esmoop.2022.100415_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1346-8138.14227","article-title":"Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: an interim analysis of a postmarketing surveillance","volume":"45","author":"Kiyohara","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.esmoop.2022.100415_bib9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.esmoop.2022.100415_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.esmoop.2022.100415_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1507\/endocrj.50.225","article-title":"A\u00a0case of fulminant type 1 diabetes with transiently positive anti-GAD antibodies","volume":"50","author":"Iwaoka","year":"2003","journal-title":"Endocr J"},{"key":"10.1016\/j.esmoop.2022.100415_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2169\/internalmedicine.42.517","article-title":"Fulminating onset type 1 diabetes with positivity for anti-GAD antibody and elevated pancreatic exocrine enzyme concentrations","volume":"42","author":"Kahara","year":"2003","journal-title":"Inter Med"},{"key":"10.1016\/j.esmoop.2022.100415_bib13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1507\/endocrj.K09E-074","article-title":"A\u00a0case of abrupt onset autoimmune type 1 diabetes mimicking fulminant type 1 diabetes","volume":"56","author":"Makino","year":"2009","journal-title":"Endocr J"},{"key":"10.1016\/j.esmoop.2022.100415_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published case reports","volume":"9","author":"Cheema","year":"2018","journal-title":"World J Oncol"},{"key":"10.1016\/j.esmoop.2022.100415_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.esmoop.2022.100415_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/s10165-008-0028-1","article-title":"Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period","volume":"18","author":"Hayashi","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.esmoop.2022.100415_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-020-01440-3","article-title":"Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients","volume":"37","author":"Morimoto","year":"2020","journal-title":"Med Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:26Z","timestamp":1761856106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000369"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100415","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100415"}}